{"id":411589,"date":"2021-01-11T06:03:12","date_gmt":"2021-01-11T11:03:12","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=411589"},"modified":"2021-01-11T06:03:12","modified_gmt":"2021-01-11T11:03:12","slug":"editas-medicine-announces-transition-of-chief-scientific-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/","title":{"rendered":"Editas Medicine Announces Transition of Chief Scientific Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., Jan.  11, 2021  (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Chief Scientific Officer, Charles Albright, Ph.D., is stepping down from the Company on January 15 to pursue another opportunity. A search is underway to find a successor to Dr. Albright.<\/p>\n<p align=\"left\">\u201cOn behalf of the entire Editas team, I sincerely thank Charlie for his many contributions in pioneering the field of genomic medicine. Charlie has been instrumental in building our scientific organization, defining our programs, and advancing our pipeline. We wish him all the best as he pursues his new role,\u201d said Cindy Collins, President and Chief Executive Officer, Editas Medicine.<\/p>\n<p align=\"left\">\u201cI have greatly enjoyed working alongside the extremely talented team here at Editas Medicine.\u00a0 Together, we advanced the revolutionary CRISPR gene editing system into a pipeline of experimental medicines,\u201d said Dr. Albright. \u201cI look forward to watching Editas Medicine\u2019s successes continue in the future, developing many transformative medicines for people in great need.\u201d<\/p>\n<p align=\"left\">\n        <strong>About\u00a0<\/strong><br \/>\n        <strong>Editas Medicine<\/strong><br \/>\n        <br \/>As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR\/Cas9 and CRISPR\/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ynD29I3VX1gd_Wn0TxB3LFzlu3Tq7zjgAYoUBKGff9s8TsZpF9X1XeyY9gJk2CRW1BlXVbBAuQ1BKA75dR9KvWs6mc5UbSkcZJKFJ_cD2qg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.editasmedicine.com<\/a>.\u00a0<\/p>\n<p align=\"left\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company\u2019s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company\u2019s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption \u201cRisk Factors\u201d included in the Company\u2019s most recent Quarterly Report on Form 10-Q, which is on file with the\u00a0Securities and Exchange Commission, and in other filings that the Company may make with the\u00a0Securities and Exchange Commission\u00a0in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzMyNiMzOTEyMTE5IzIwMjYwMjc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/4eef3ee8-bcb9-422a-9701-dbd4ff4eba21\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Contacts:\r\nMedia\r\nCristi Barnett\r\n(617) 401-0113 \r\ncristi.barnett@editasmed.com\r\n\r\nInvestors\r\nEditas Medicine Investor Relations\r\n(617) 401-9052\r\nir@editasmed.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Chief Scientific Officer, Charles Albright, Ph.D., is stepping down from the Company on January 15 to pursue another opportunity. A search is underway to find a successor to Dr. Albright. \u201cOn behalf of the entire Editas team, I sincerely thank Charlie for his many contributions in pioneering the field of genomic medicine. Charlie has been instrumental in building our scientific organization, defining our programs, and advancing our pipeline. We wish him all the best as he pursues his new role,\u201d said Cindy Collins, President and Chief Executive Officer, Editas Medicine. \u201cI have greatly enjoyed working alongside the extremely &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Editas Medicine Announces Transition of Chief Scientific Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-411589","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Editas Medicine Announces Transition of Chief Scientific Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Editas Medicine Announces Transition of Chief Scientific Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Chief Scientific Officer, Charles Albright, Ph.D., is stepping down from the Company on January 15 to pursue another opportunity. A search is underway to find a successor to Dr. Albright. \u201cOn behalf of the entire Editas team, I sincerely thank Charlie for his many contributions in pioneering the field of genomic medicine. Charlie has been instrumental in building our scientific organization, defining our programs, and advancing our pipeline. We wish him all the best as he pursues his new role,\u201d said Cindy Collins, President and Chief Executive Officer, Editas Medicine. \u201cI have greatly enjoyed working alongside the extremely &hellip; Continue reading &quot;Editas Medicine Announces Transition of Chief Scientific Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-11T11:03:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzMyNiMzOTEyMTE5IzIwMjYwMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-transition-of-chief-scientific-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-transition-of-chief-scientific-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Editas Medicine Announces Transition of Chief Scientific Officer\",\"datePublished\":\"2021-01-11T11:03:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-transition-of-chief-scientific-officer\\\/\"},\"wordCount\":536,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-transition-of-chief-scientific-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzMyNiMzOTEyMTE5IzIwMjYwMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-transition-of-chief-scientific-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-transition-of-chief-scientific-officer\\\/\",\"name\":\"Editas Medicine Announces Transition of Chief Scientific Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-transition-of-chief-scientific-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-transition-of-chief-scientific-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzMyNiMzOTEyMTE5IzIwMjYwMjc=\",\"datePublished\":\"2021-01-11T11:03:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-transition-of-chief-scientific-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-transition-of-chief-scientific-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-transition-of-chief-scientific-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzMyNiMzOTEyMTE5IzIwMjYwMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzMyNiMzOTEyMTE5IzIwMjYwMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-announces-transition-of-chief-scientific-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Editas Medicine Announces Transition of Chief Scientific Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Editas Medicine Announces Transition of Chief Scientific Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/","og_locale":"en_US","og_type":"article","og_title":"Editas Medicine Announces Transition of Chief Scientific Officer - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Chief Scientific Officer, Charles Albright, Ph.D., is stepping down from the Company on January 15 to pursue another opportunity. A search is underway to find a successor to Dr. Albright. \u201cOn behalf of the entire Editas team, I sincerely thank Charlie for his many contributions in pioneering the field of genomic medicine. Charlie has been instrumental in building our scientific organization, defining our programs, and advancing our pipeline. We wish him all the best as he pursues his new role,\u201d said Cindy Collins, President and Chief Executive Officer, Editas Medicine. \u201cI have greatly enjoyed working alongside the extremely &hellip; Continue reading \"Editas Medicine Announces Transition of Chief Scientific Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-11T11:03:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzMyNiMzOTEyMTE5IzIwMjYwMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Editas Medicine Announces Transition of Chief Scientific Officer","datePublished":"2021-01-11T11:03:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/"},"wordCount":536,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzMyNiMzOTEyMTE5IzIwMjYwMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/","name":"Editas Medicine Announces Transition of Chief Scientific Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzMyNiMzOTEyMTE5IzIwMjYwMjc=","datePublished":"2021-01-11T11:03:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzMyNiMzOTEyMTE5IzIwMjYwMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzMyNiMzOTEyMTE5IzIwMjYwMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-announces-transition-of-chief-scientific-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Editas Medicine Announces Transition of Chief Scientific Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=411589"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411589\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=411589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=411589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=411589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}